

1 Multi-level modeling and multiple group analysis of disparities in  
2 continuity of care and viral suppression among Nigerian adolescents and  
3 youths living with HIV

4  
5 Okikiolu Abimbola Badejo<sup>1,2,3§</sup>, Christiana Noestlinger<sup>2</sup>, Toyin Jolayemi<sup>1</sup>, Juliet Adeola<sup>1</sup>, Prosper  
6 Okonkwo<sup>1</sup>, Sara Van Belle<sup>2</sup>, Edwin Wouters<sup>3</sup>, Marie Laga<sup>2</sup>

7  
8  
9 1 APIN Public Health Institute, Abuja, Nigeria  
10 2 Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium  
11 3 Department of Sociology, University of Antwerp, Antwerp, Belgium

12  
13  
14

15 § Corresponding author: Okikiolu Abimbola Badejo

16 10 Ndagi Mamudu Street  
17 Jabi, Abuja, Nigeria  
18 +2348025419082  
19 Email: [Okikolubadejo@gmail.com](mailto:Okikolubadejo@gmail.com) ; [Obadejo@ext.itg.be](mailto:Obadejo@ext.itg.be)

20

21 E-mail addresses of authors:

22 CN: [cnoestlinger@itg.be](mailto:cnoestlinger@itg.be)

23 TJ: [tjolayemi@apin.org.ng](mailto:tjolayemi@apin.org.ng)

24 JA: [jadeola@apin.org.ng](mailto:jadeola@apin.org.ng)

25 CN: [cnoestlinger@itg.be](mailto:cnoestlinger@itg.be)

26 TJ: [pokonkwo@apin.org.ng](mailto:pokonkwo@apin.org.ng)

27 SVB: [svbelle@itg.be](mailto:svbelle@itg.be)

28 CN: [cnoestlinger@itg.be](mailto:cnoestlinger@itg.be)

29 EW: [edwin.wouters@uantwerpen.be](mailto:edwin.wouters@uantwerpen.be)

30 ML: [mlaga@itg.be](mailto:mlaga@itg.be)

31

32 Keywords: HIV care, retention, viral suppression, adolescent, youth

33 **Abstract**

34 **Introduction:** Substantial disparities in care outcomes exist between different sub-groups of  
35 adolescents and youths living with HIV(ALHIV). Understanding variation in individual and  
36 health-facility characteristics could be key to identifying targets for interventions to reduce these  
37 disparities. We modeled variation in ALHIV retention in care and viral suppression, and quantified  
38 the extent to which individual and facility characteristics account for observed variations.

39 **Methods:** We included 1,177 young adolescents (10-14 years), 3,206 older adolescents (15-19  
40 years) and 9,151 young adults (20-24 years) who were initiated on antiretroviral therapy (ART)  
41 between January 2015 and December 2017 across 124 healthcare facilities in Nigeria. For each  
42 age-group, we used multilevel modeling to partition observed variation of main outcomes(retention  
43 in care and viral suppression at 12 months post ART initiation) by individual (level one) and health  
44 facility (level two) characteristics. We used multiple group analysis to compare the effects of  
45 individual and facility characteristics across age-groups.

46 **Results:** Facility characteristics explained most of the observed variance in retention in care in all  
47 the age-groups, with smaller contributions from individual-level characteristics (14-22.22% vs 0 -  
48 3.84%). For viral suppression, facility characteristics accounted for a higher proportion of variance  
49 in young adolescents (15.79%), but not in older adolescents (0%) and young adults(3.45%). Males  
50 were more likely to not be retained in care(aOR=1.28;  $p<0.001$  young adults) and less likely to  
51 achieve viral suppression (aOR=0.69;  $p<0.05$  older adolescent). Increasing facility-level viral load  
52 testing reduced the likelihood of non-retention in care, while baseline regimen TDF/3TC/EFV or  
53 NVP increased the likelihood of viral suppression.

54 **Conclusions:** Differences in characteristics of healthcare facilities accounted for observed  
55 disparities in retention in care and, to a lesser extent, disparities in viral suppression. An optimal  
56 combination of individual and health-services approaches is, therefore, necessary to reduce  
57 disparities in the health and wellbeing of ALHIV.

58  
59  
60  
61  
62  
63

64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98

## **Key Messages**

### **What is already known?**

- Adolescents and youths living with HIV have worse care and treatment outcomes compared to other groups
- Significant disparity in care and treatment outcomes exist between different adolescent and youth subgroups

### **What are the new findings?**

- Differences in characteristics of healthcare facilities delivering services are associated with disparities in outcomes within and across adolescent and youth age-groups.

### **What do the new findings imply?**

- An optimal combination of individual and health-services approaches is necessary to reduce disparities in the health and wellbeing of adolescent and youths living with HIV.

## 99           **1. Introduction**

100   Adolescents and youths are an important group in global efforts to eliminate HIV. Compared to  
101   adults, adolescents and youths engage less with health care services and have lower viral  
102   suppression rates (1–5), resulting in increases in AIDS-related deaths despite a global reduction of  
103   AIDS-mortality among other age-groups (6–8). Under current circumstances, the global optimism  
104   to eliminate HIV by 2030 does not appear to hold for adolescents and youths (9,10).

105  
106   Sub-optimal outcomes among adolescents and youths living with HIV (ALHIV) has been ascribed  
107   to unique individual vulnerabilities due to developmental factors associated with transitioning to  
108   adulthood (11–13). However, recent research suggests that such poor outcomes also demonstrate a  
109   failure of clinical care services to address the unique needs of ALHIV as they transition to  
110   adulthood. Research in this area seeks to identify and modify aspects of health services to be more  
111   adolescent and youth-friendly to improve care and treatment outcomes. Although some of these  
112   efforts highlight some promising strategies results have been mixed (14–24). More important,  
113   much of the research does not sufficiently disentangle the multi-layered influences of individual-  
114   and health services factors. This is important because delineating the relative contributions of  
115   individual and higher-level factors can inform the design of specific individual- or higher-level  
116   interventions across often different and heterogeneous ALHIV groups and communities.

117  
118   In this multilevel study, we, therefore, examined the interplay of factors influencing ALHIV  
119   outcomes at the individual- and health-services levels as they relate to retention in care and viral  
120   suppression among a large sample of ALHIV in Nigeria. Nigeria accounts for a significant  
121   proportion of ALHIV burden in sub-Saharan Africa, and one of the few countries where mortality  
122   among ALHIV continues to increase (25). The national HIV program began in 2002 in only 25  
123   public (government-owned) tertiary-level healthcare facilities. Gradual decentralization since then  
124   has resulted in an increased mix in types and levels of health care facilities delivering HIV services  
125   (26). While this has significantly increased access to HIV services, it has also brought about  
126   heterogeneity in terms of how national HIV guidelines are interpreted and implemented. The extent  
127   to which these differences in service delivery channels have shaped HIV-related outcomes have  
128   received little attention partly because of little information sharing between the public and private  
129   health sectors. Our study will characterize how this heterogeneity operates alongside individual-

130 level characteristics to affect retention in care and viral suppression within and between ALHIV  
131 age-groups, thereby enabling the development of more context-appropriate individual or service-  
132 delivery interventions. We hypothesize that differences in characteristics of healthcare facilities  
133 delivering services to ALHIV will be associated with differences in these outcomes within and  
134 across ALHIV age-groups.

135

136

## 137 **2. Methods**

138

### 139 **Study setting and study population**

140 Nigeria is administratively divided into 36 states and within these states, comprehensive HIV  
141 services are freely provided by the Government of Nigeria with funding support from the US  
142 President's Emergency Plan for AIDS Relief (PEPFAR). Our study covered two of the 36 states  
143 (Benue and Plateau).

144 We retrospectively evaluated routine data for ALHIV enrolled in HIV care and treatment between  
145 1 January 2015 to 31 December 2017 within a network of healthcare facilities supported by the  
146 APIN Public Health Initiatives Ltd/Gte treatment network (APIN). APIN is a PEPFAR  
147 implementing agency that provides technical and programmatic support to 285 health-care  
148 facilities to deliver comprehensive HIV care and treatment, spread across 95 local government  
149 areas (LGAs) in eight states of Nigeria (the country has a total of 774 LGAs distributed across 36  
150 states; LGAs may be the equivalent of districts in other settings). The cohort for this study was  
151 enrolled in HIV care across 124 secondary and tertiary level healthcare facilities in two of the  
152 program's eight states (Benue and Plateau states). Secondary facilities provide HIV services within  
153 a generalist, non-specialized clinic setting, while tertiary facilities provide services in specialist  
154 hospital settings. Healthcare facilities were included if they had provided comprehensive HIV  
155 prevention, care, and treatment services for at least one year at the time of the study.

156

157

158

159 **Enrollment into care and follow-up**

160 All ALHIV in our study received free comprehensive HIV care according to Nigeria's national  
161 guidelines for HIV prevention, care, and treatment, which is regularly updated according to the  
162 WHO recommendations. These include antiretroviral treatment (ART) for children, adolescents,  
163 and adults, the prevention of mother-to-child-transmission services (PMTCT); laboratory services  
164 including viral load, CD4 count, routine safety monitoring of laboratory test results; and pharmacy  
165 services.

166 **Outcome variables**

167 **Retention in care:** To assess this outcome, we adapted indicators 1.2 and 1.3 of the Global AIDS  
168 Monitoring tool (GAM) (27). GAM indicator 1.2 describes the proportion of people living with  
169 HIV who are on antiretroviral therapy including people reinitiating antiretroviral therapy after  
170 previously having stopped treatment or being classified as lost to follow-up. We adapted this  
171 indicator to define retention according to the pattern of care-engagement at three-time points (30  
172 days, 90 days, and 365 days) within the first 12 months after initiating ART. ALHIV were  
173 considered retained in care if they established care contact at all the three time points as evidenced  
174 by documented clinic visit and/or drug pick up. ALHIV were considered to have interrupted care  
175 if they missed care contact on one or two of the three time-points, and classified as lost to follow  
176 up (LTF) if there was no care contact at all three time-points after initiating ART.

177

178 **Viral suppression:** GAM indicator 1.3 assesses the percentage and number of adults and children  
179 living with HIV who have suppressed viral load and tracks progress towards the third 90 of  
180 UNAIDS 90-90-90 targets (28). For the numerator, the GAM recommends reporting the estimated  
181 number of people who have suppressed viral load if viral load testing coverage (i.e., the number of  
182 people routinely tested among all people on treatment) is  $\geq 50\%$ ; or reporting only the number of  
183 routine viral load tests if viral load testing coverage is less than 50%. As the viral load coverage in  
184 our study population exceeded 50%, we adapted both the numerator (viral suppression rates) as our  
185 second outcome and the denominator (viral load testing coverage) as one of the explanatory  
186 variables at the service-delivery level (described below). Consistent with the GAM indicator 1.3  
187 we defined viral suppression as HIV-RNA viral load  $< 1000$  copies/ml. Although national policy  
188 recommends a viral load test at 12 months, we used viral load tests conducted within a 12-18 month

189 window after ART initiation to allow some time for viral load testing among tracked ALHIV who  
190 returned to care following care interruption or LTF

191

## 192 **Exposure variables**

### 193 **Individual-level data measures**

194 We included demographic and clinical information routinely collected at baseline during  
195 enrollment into HIV care. Demographic information collected included age at enrolment, sex,  
196 marital status, pregnancy status, level of education. Clinical characteristics included CD4 cells/ml  
197 count at enrollment, TB status, WHO clinical stage, ART regimen received. Information about the  
198 follow-up drug or clinic appointments visits were also available.

199

### 200 **Facility-level measures**

201 We used variables at the health care facility level to assess characteristics at the service delivery  
202 level. Such information included type/level of services offered (secondary or tertiary level care),  
203 the facility size (i.e. total number of ALHIV enrolled in care categorized as < 200, 200 - 500, >  
204 500), viral load test coverage (proportion of enrolled ALHIV who have had at least one viral load  
205 test at 12 months or more after initiating ART) and whether the health facility was a designated  
206 adolescent/youth friendly center. Adolescents and youth centers within the APIN program refer to  
207 any healthcare facility implementing dedicated services to adolescents and youths in addition to  
208 routine HIV service provision. Such services are focused on modifying certain structures of care  
209 to be adolescent-friendly and may include re-organizing or changing the location of the clinic,  
210 dedicated clinic days, availability of peer support groups, adolescent-provider communication  
211 modalities, appointment availability and scheduling, and trained providers for adolescents and  
212 youth.

213

### 214 **Data management**

215 We retrieved de-identified clinical data from the APIN/PEPFAR electronic database, which  
216 routinely captures patient demographic, clinical, and laboratory data. APIN supports health facility  
217 information systems with relational database management that is opensource (OpenMRS;  
218 [www.openmrs.com](http://www.openmrs.com)).

219

220

## 221 **Statistical analysis**

222 We first conducted descriptive analyses of baseline individual and facility-level characteristics  
223 using proportions, frequencies, means, and median. ALHIV in the cohort were categorized into  
224 three age-groups (10-14 years young adolescents, 15-19 years older adolescents, 20-24 years young  
225 adults) and the baseline characteristics were compared for the three age-groups using chi-square  
226 statistics. Next, we conducted a bivariate analysis of age-group comparisons of patterns of retention  
227 in care and viral measures.

228 To develop multi-level models to examine the association between individual- and facility-level  
229 factors and the two outcomes of interest (retention in care and viral suppression), we adopted a  
230 binary outcome logistic multilevel modeling approach, partitioning each outcome's variance by its  
231 individual- (level one) and facility-level (level two) components concurrently to account for the  
232 nested structure of our data. In this approach, we allow the model intercepts to vary at random. We  
233 conducted the modeling analysis in three steps. In the first step (Model 1, null model) we did not  
234 include any explanatory variable, allowing an estimate of the total variation in outcomes by health  
235 facilities. In the second step (Model 2), we included only individual-level factors. This step allowed  
236 us to test whether or how much of the total random variation observed in the first stage could be  
237 explained by our individual-level data. In the third step (Model 3) we added facility-level factors  
238 to Model 2. This allowed us to test whether or how much of the random variation could be  
239 explained by the facility-level characteristics. For each outcome, we repeated these model steps for  
240 each of our three ALHIV age-group.

241 **Measures of association (fixed effects)** in our models are presented as odds ratios (ORs) and their  
242 p-values.

243 **Measures of variation (random effects)** in the models are random slope variance, intra-cluster  
244 correlation (ICC), and explained variation. Random slope variance indicates whether a contextual  
245 phenomenon differs in magnitude for different groups and whether the facility level modifies  
246 associations between individual-level exposures.

247

248 To check whether the effect of explanatory variables differed across ALHIV age-groups, we  
249 conducted a multiple group analysis. We used *mysuest* program to combine models from the three



250 ALHIV age-groups and then used *miteststransform* command to test for equality of each variable  
251 coefficients across the three age-groups using a 5% significance threshold.

252 To minimize potential bias due to missing data, we performed multiple imputations with chained  
253 equations after data exploration to verify that data were missing at random. A total of 163 data  
254 imputations were done as determined by the STATA module “how\_many\_imputations” (29)  
255 All statistical analyses were conducted using Stata version 16.1 (Stata Corporation, College  
256 Station, Texas, USA).

257

### 258 **Ethics**

259 As part of the APIN protocol written informed consent and, where necessary, assent for service  
260 provision and participation (or data use) for future evaluations were obtained at the point of  
261 enrollment into HIV care and treatment. Adolescents or minors less than 15 years at enrolment  
262 provide another written and signed informed consent as soon as they become 15 years or older  
263 when transferred/transitioned to the adult ART program. Ethical approval for this study was  
264 obtained from the IRBs of APIN and the Institute of Tropical Medicine, Antwerp.

265

## 266 **3. Results**

### 267 **Baseline characteristics**

268 Our study included a total of 13,527 AYLHIV who were initiated on ART between 1 January 2015  
269 and 31 December 2017. Table 1 below presents the baseline characteristics.

270 The demographic and clinical characteristics of the study population at ART initiation were  
271 compared by three age-groups 10-14 years, 15-19 years, and 20-24 years. The three age-groups  
272 were similar in terms of pregnancy status and TB status at baseline ( $p=0.06$ ,  $p=0.27$  respectively)  
273 but differed in other characteristics. As expected, young adolescents (10-14years) were  
274 predominantly single ( $p<0.00$ ), with the highest level of education at the primary level ( $p<0.00$ ).  
275 Compared to the other age-groups, young adolescents also had higher enrollment at a tertiary  
276 healthcare facility ( $p<0.00$ ), presented earlier for treatment (Median CD4 399cells/ML with mostly  
277 mild or no immune deficiency at baseline). Predominant ART regimen at baseline among young  
278 adolescents was ABC or AZT/3TC/EFV or NVP, compared to the other age-groups that were

279 predominantly initiated on TDF/3TC/EFV or NVP. Older adolescents and young adult ART  
 280 enrollees were almost exclusively female (82.9-88.1%), commonly married (42.9-59.8%), and  
 281 educated up to a secondary or higher level of education (43.8- 47.6%)

282

283 Table 1: Baseline Characteristics of ALHIV by age-group

Characteristics	Total	Young Adolescents (10-14years)	Older Adolescents (15-19years)	Young Adults (20-24 years)	X p-value
AYLHIV (N, %)	13,527(100%)	1,177 (8.7)	3,206 (23.7)	9,151 (67.6)	
Female, n (%)	11,380 (84.1)	656 (56.1)	2,658 (82.9)	8,066 (88.1)	
<b>Age at enrolment (Median, IQR)</b>	21 (19-23)	12 (10-13)	18 (17-19)	22(21-23)	
Female	21 (19-23)	10 (12-13)	18(17-19)	22 (21-23)	
Male	20 (15-22)	10(12-13)	17 (16-18)	22(21-24)	
<b>Marital Status, n (%)</b>					0.000
Single	1,481 (33.4)	169 (82.4)	492 (46.6)	820 (25.9)	
Married	2,365 (53.4)	18 (8.8)	453 (42.9)	1,894 (59.8)	
Others	581 (13.1)	18 (8.8)	111 (10.5)	453 (14.3)	
Missing	9,100	965	2,150	5,985	
<b>Pregnancy status, n (% of females)</b>					0.06
Pregnant	121 (1)	1 (0.2)	32 (1.2)	88 (1.1)	
Non-pregnant	8,971 (99)	130 (99.8)	2,031 (98.8)	6810 (98.9)	
Missing	2,288	525	595	1,168	
<b>Education, n (%)</b>					0.00
None/Informal	1072 (34.6)	45 (31)	257 (33.7)	770 (35.1)	
Primary	610 (19.7)	60 (41.4)	171 (22.4)	379 (17.3)	
Secondary and higher	1418 (45.7)	40 (27.6)	334 (43.8)	1044 (47.6)	
Missing	10,427	1025	2444	6958	
<b>Level of care, n(%)</b>					
Secondary	12658 (93.6)	1041 (89)	2940 (91.7)	8677 (94.8)	0.00
Tertiary	869 (6.4)	129 (11)	266 (8.3)	474 (5.2)	
<b>Year of ART initiation, n (%)</b>					0.00
2015	4509 (33.3)	343 (29.3)	1037 (32.3)	3129 (34.2)	
2016	4997 (36.9)	430 (36.8)	1233 (38.5)	3334 (36.4)	
2017	4021 (29.7)	397 (33.9)	936 (29.2)	2688 (29.4)	
<b>Baseline CD4 cells/ml (Median, IQR)</b>	345 (198-516)	399 (185-634)	348 (201-515)	337 (198-508)	
<b>Baseline immunodeficiency, n(%)</b>					0.00
None (CD4≥500cells/ml)	1432 (26.9)	157 (34.9)	346 (27)	929 (25.8)	
Mild (CD4≥350-499cells/ml)	1190 (22.3)	100 (22.3)	287 (22.4)	803 (22.3)	
Advanced (CD4≥200-349cells/ml)	1364 (25.6)	76 (16.9)	332 (25.9)	956 (26.6)	
Severe (CD4 < 200cells/ml)	1342 (25.2)	116 (25.8)	316 (24.7)	910 (25.3)	
Missing	8199	721	1925	5553	
<b>TB Status at baseline, n (%)</b>					0.27
No signs or symptoms of TB	7442 (92.7)	589 (92.9)	1794 (92.6)	5059 (92.7)	
Presumptive or confirmed TB	443 (5.5)	32 (5)	100 (5.2)	311 (5.7)	
On IPT	143 (1.8)	13 (2.1)	44 (2.3)	86 (1.6)	
Missing	5499	536	1268	3695	
<b>WHO Stage, n(%)</b>					0.00
1	6475 (77.7)	493 (74)	1584 (79.3)	4398 (77.6)	
2	1272 (15.3)	105 (15.8)	274 (13.7)	893 (15.8)	
3	517 (6.2)	61 (9.2)	119 (6)	337 (5.9)	
4	67 (0.8)	7 (1)	21 (1)	39 (0.7)	
Missing	5196	504	1208	3484	
<b>Baseline ART Regimen, n(%)</b>					0.00
ABC or AZT/3TC/EFV or NVP	2048 (15.1)	740 (63.2)	466 (14.5)	842 (9.2)	
ABC or AZT/3TC/ATVr or LPVr	38 (0.3)	9 (0.8)	16 (0.5)	13 (0.1)	
TDF/3TC/EFV or NVP	11349 (83.9)	409 (35)	2691( 83.9)	8249 (90.1)	
TDF/3TC/ATVr or LPVr	32 (0.2)	2 (0.2)	18 (0.6)	12 (0.1)	
Others	60 (0.4)	10 (0.9)	15 (0.5)	35 (0.4)	

284 **Retention in care and viral outcomes**


285 The overall proportion of ALHIV who had viral load testing was higher among young adolescents  
286 compared to older adolescents and young adults (59.1% vs 49.5% and 51.3%). Of ALHIV who  
287 had viral load testing, the proportion with VL less than 1000 copies/mL was lower among younger  
288 adolescents compared to older adolescents and young adults (63.5% vs 81.2% and 88.3%) (Figure  
289 1)

290 Viral load testing and viral suppression varied between age-groups by the pattern of care continuity.  
291 For ALHIV retained in care, the proportion who had viral load testing was highest among young  
292 adolescents (78%) compared to older adolescents (73%) and young adults (75%). Among retained  
293 ALHIV who had viral load testing, the viral suppression rate (the proportion that was virally  
294 suppressed) was lowest among young adolescents (49%) compared to older adolescents (84%) and  
295 young adults (90%).

296 For ALHIV lost to follow up, the proportion who had viral load testing was similar across the age-  
297 groups, ranging between 4-6%. Among ALHIV lost to follow up who had viral load testing young  
298 adolescents had the lowest viral suppression rate (44%) compared to older adolescents (55%) and  
299 young adults (75%).

300 For ALHIV who had interrupted care, the proportion who had viral load testing was highest among  
301 young adolescents (45%) compared to older adolescents (40%) and young adults (40%). Among  
302 ALHIV with interrupted care who had viral load testing young adolescents had the lowest  
303 proportion with viral suppression or viral suppression rate (48%) compared to older adolescents  
304 (69%) and young adults (79%).

305



306 Figure 1 Retention in care and viral outcomes.

307

### 308 Measures of associations (fixed effects)

309

#### 310 Continuity in care

311 Table 2 shows both fixed-effect (measures of association) and random-effects (measures of  
 312 variation) from the multilevel analysis by age-group with non-retention in care as the outcome.

313 Young adolescents: After controlling for both individual and facility characteristics the likelihood  
 314 for non-retention was lower among young adolescents initiated on the ART regimen category  
 315 ‘Others’ compared to young adolescents initiated on a regimen consisting of ABC or AZT/3TC/  
 316 ATVr or LPVr (aOR=0.25;  $p<0.05$  ). The likelihood of non-retention in care reduced with  
 317 increasing viral load testing coverage among young adolescents ALHIV. For each one-unit  
 318 increase in health facility viral load test coverage, the odds of non-retention in this group decreased  
 319 by 1% (aOR=0.99;  $p<0.001$ ).

320

321 Older adolescents: In this group non-retention was less likely among those enrolled in 2017  
322 compared to enrollees in 2015 (aOR=0.74;  $p<0.001$ ); no significant association between retention  
323 and any other individual-level factor was observed. At the level of health facility, the likelihood of  
324 non-retention in care reduced with increasing viral load testing coverage among enrolled AYLHIV.  
325 For each one-unit increase in health facility viral load test coverage, the odds of non-retention  
326 among older adolescents decreased by 7% (aOR=0.93;  $p<0.001$ ).

327  
328 Young adults: In this group, the odds of non-retention was higher among males (aOR=1.28;  
329  $p<0.001$ ) compared to females; the odds for non-retention was lower among those initiated on the  
330 ART regimen category ‘Others’ compared to those initiated on regimen ABC or AZT/3TC/ATVr  
331 or LPVr (aOR=0.15;  $p<0.05$ ). At the level of the health facility, the likelihood of non-retention in  
332 care reduced with increasing viral load testing coverage among enrolled AYLHIV. For each one-  
333 unit increase in health facility viral load test coverage, the odds of non-retention among young  
334 adults decreased by 2% (aOR=0.98;  $p<0.001$ ).

335

### 336 **Viral suppression**

337 Table 3 shows both fixed-effect (measures of association) and random-effects (measures of  
338 variation) from the multilevel analysis by age-group with viral suppression as the outcome.

339  
340 Young adolescents: After controlling for both individual and facility-level characteristics, young  
341 adolescents who interrupted care were less likely to achieve viral suppression, compared to those  
342 retained (aOR=0.4;  $p<0.001$ ). No facility-level characteristic was significantly associated with viral  
343 suppression in the age group.

344 Older adolescent ALHIV: The odds for viral suppression was higher among married, compared to  
345 single older adolescents (aOR=1.74;  $p<0.05$ ). Compared to older adolescents with no immune  
346 suppression at baseline, those with severe immune suppression at baseline had a reduced likelihood  
347 of achieving viral suppression (aOR= 0.54;  $p<0.05$ ). Compared to older adolescents retained in  
348 care, the odds for viral suppression was lower among older adolescents who were lost to follow up  
349 (aOR=0.19;  $p<0.001$ ) or who interrupted care (aOR=0.41;  $p<0.001$ ).

350

351 Young adults: Compared to young adults with no immune suppression at baseline, those with  
352 severe immune suppression at baseline had a reduced likelihood of achieving viral suppression  
353 (aOR= 0.55;  $p<0.001$ ). Young adults initiated on ART regimen TDF/3TC/EFV or NVP had higher  
354 odds of achieving viral suppression compared to young adults initiated on ABC or AZT/3TC/  
355 ATVr or LPVr (aOR= 6.47;  $p<0.05$ ). Compared to young adults retained in care, the odds for viral  
356 suppression was lower among those who were lost to follow up (aOR=0.35;  $p<0.001$ ) or who  
357 interrupted care (aOR=0.42;  $p<0.001$ ).

358

### 359 **Measures of variations (random effects)**

#### 360 **Retention in care**

361 The results of the null models (Model 1) across ALHIV age-groups showed significant variance of  
362 12-14% in the log-odds of non-retention in care attributed to health facilities [ $\tau =0.47$ ;  $p<0.0001$   
363 (young adolescents),  $\tau =0.52$ ;  $p<0.0001$  (older adolescents),  $\tau = 0.54$ ;  $p<0.0001$  (young adults)].  
364 The variations at health facility level remained statistically significant even after controlling for  
365 individual-level (Model 2) and facility-level characteristics (Model 3), thereby lending support for  
366 the use of multilevel modeling to account for variations at the two levels. As judged by the  
367 proportional change in variance among young adolescents 4.26% of the variance in retention across  
368 health facilities was explained by individual factors (Model 2) and 22.223% of the variation  
369 explained by facility factors (Model 3). For older adolescents, 3.84% of this variance in retention  
370 was explained by individual factors alone (Model 2) and 14% explained by facility factors (Model  
371 3). For young adults, none of the variations in retention was explained by individual factors alone  
372 (Model 2) while 16.67% was explained by both individual and facility factors (Model 3)

373

#### 374 **Viral suppression**

375 The results of the null models (Model 1) across ALHIV age-groups show significant variance of  
376 9-13% in the log-odds of viral suppression attributed to health facilities [ $\tau =0.39$ ;  $p<0.05$  (young  
377 adolescents),  $\tau =0.49$ ;  $p<0.0001$  (older adolescents),  $\tau = 0.34$ ;  $p<0.0001$  (young adults)]. The  
378 variations at the health facility level also remained statistically significant even after controlling  
379 for individual-level and facility-level factors. As judged by the proportional change in variance  
380 among young adolescents 2.56% of the variance in viral suppression across health facilities was

381 explained by individual factors alone (Model 2) and 15.79% of the variation explained by facility  
382 factors (Model 3). For older adolescents, 10.2% of this variance in viral suppression was explained  
383 by individual factors alone (Model 2), while facility factors did not explain any of the variance  
384 (Model 3). For young adults, 14.71% of the variation was explained by individual factors alone  
385 (Model 2) and 3.45% by facility factors (Model 3).

386  
387 **Multiple-group analysis**

388 We detected statistically significant group differences in the association between retention in care  
389 and two variables: sex and ART regimen at baseline (Table 2).

390 The association between sex and retention in care differed in magnitude and direction of effects  
391 across the age-groups, reaching statistical significance only among young adults. with male young  
392 adults having an increased likelihood of not being retained in care (aOR 1.28,  $p < 0.00$ ).

393 The association between ART regimen at baseline and retention in care had similar direction but  
394 differed in the magnitude of effects across the age-groups. Initiation of regimen baseline ‘Others’  
395 was associated with a reduced likelihood of not being retained in care in the three age-groups, with  
396 effect highest among young adults and lowest among older adolescents.

397 We did not find any significant group differences in the association between any of the explanatory  
398 variables and viral suppression (Table 3).

399

400

401

402

403

404

405

406

407

408

Characteristics	Young Adolescents (10-14 years)			Older Adolescents (15-19 years)			Young Adults (20-24 years)			Equality of Coefficient (p-value)
	Model 1 OR	Model 2 aOR	Model 3 aOR	Model 1 OR	Model 2 aOR	Model 3 aOR	Model 1 OR	Model 2 aOR	Model 3 aOR	
<b>LEVEL 1: INDIVIDUALS</b>										
<b>Sex</b>										5.02 (0.00)
Female										
Male		0.86	0.86		0.90	0.89		1.28**	1.28**	
<b>Marital Status</b>										0.44(0.65)
Single										
Married		1.15	1.14		0.85	0.85		0.89	0.89	
Others		1.13	1.12		0.91	0.90		0.97	0.96	
<b>Education level</b>										0.11(0.89)
None/Informal										
Primary		0.89	0.89		1.03	1.03		1.01	1.00	
Secondary and higher		1.01	1.01		0.92	0.92		0.95	0.94	
<b>Year of ART initiation</b>										1.37(0.25)
2015										
2016		0.83	0.83		0.91	0.90		0.99	0.99	
2017		0.85	0.86		0.75**	0.74**		0.91	0.91	
<b>WHO Stage</b>										0.42(0.66)
1										
2		0.83	0.83		0.96	0.96		0.92	0.91	
3		0.82	0.82		0.94	0.94		1.01	1.01	
4		1.25	1.27		1.13	1.12		1.02	1.02	
<b>Baseline immunosuppression</b>										0.23(0.79)
None (CD4≥500cells/ml)										
Mild (CD4≥350-499cells/ml)		1.09	1.09		1.03	1.03		1.08	1.08	
Advanced (CD4≥200-349cells/ml)		1.24	1.24		1.02	1.03		1.09	1.09	
Severe (CD4 < 200cells/ml)		1.31	1.31		1.13	1.15		1.17	1.17	
<b>Baseline TB status</b>										0.11 (0.89)
No signs or symptoms of TB										
Presumptive or confirmed TB		1.01	1.01		0.96	0.94		1.02	1.01	
On IPT		0.88	0.89		1.25	1.26		0.82	0.82	
<b>ART regimen at baseline</b>										6.23 (0.00)
ABC or AZT/3TC/ ATVr or LPVr										
ABC or AZT/3TC/EFV or NVP		1.47	1.48		2.36	2.36		2.04	2.18	
TDF/3TC/EFV or NVP		1.52	1.50		2.79	2.79		1.82	1.87	
TDF/3TC/ATVr or LPVr		1.04	1.06		1.07	1.07		3.34	3.39	
Others		0.23*	0.25*		1	1		0.14*	0.15*	

<b>LEVEL 2: Health Facility</b>										
<b>Level of care</b>										2.55(0.08)
Secondary										
Tertiary			1.10			0.93			1.38	
<b>Patient volume (AYLHIV)</b>										1.48(0.23)
<200										
200-400			1.07			1.20			1.29	
>500			1.03			0.65			0.67	
<b>Designated AYFS facility</b>										1.38 (0.25)
Yes										
No			0.85			1.04			0.93	
<b>Viral load testing coverage</b>			0.99**			0.93**			0.98**	0.79(0.45)

<b>Random effects model</b>										
Health Facility level										
Variance estimate	0.47**	0.45**	0.35**	0.52**	0.50**	0.43**	0.54**	0.54**	0.45**	
Explained variation (%)	Ref	4.26 <sup>a</sup>	22.22 <sup>b</sup>	Ref	3.84 <sup>c</sup>	14 <sup>d</sup>	Ref	0 <sup>e</sup>	16.67 <sup>f</sup>	
ICC (%)	0.12	0.12	0.10	0.14	0.13	0.12	0.14	0.14	0.12	

410 \* p<0.05; \*\* p<0.00

411 Model 1 is the null model; baseline model without any variable

412 Model 2 is model adjusted for individual-level variables,

413 Model 3 is additionally adjusted for facility-level covariates

414 a: Explained facility-level variance due to individual factors alone = (.47-.45)/.47 = 4.26%

415 b: Explained facility-level variance due to facility characteristics = (.45-.35)/.45 = 22.22%

416 c: Explained facility-level variance due to individual factors = (.52-.50)/.52 = 3.84%

417 d: Explained facility-level variance due to facility characteristics = (.50-.43)/.50 = 14%

418 e: Explained facility-level variance due to individual factors alone = (.54-.54)/.54 = 0%

419 f: Explained facility-level variance due to facility characteristics = (.54-.45)/.54 = 16.67%



Characteristics	Young Adolescents (10-14 years)			Older Adolescents (15-19 years)			Young Adults (20-24 years)			Equality of Coefficient (p-value)
	Model 1	Model 2	Model 3	Model 1	Model 2	Model 3	Model 1	Model 2	Model 3	
<b>LEVEL 1: INDIVIDUALS</b>	OR	aOR	aOR	OR	aOR	aOR	OR	aOR	aOR	
<b>Sex</b>										1.12(0.33)
Female										
Male		0.73	0.73		0.69*	0.69*		0.93	0.94	
<b>Marital Status</b>										0.67(0.51)
Single										
Married		1.77	1.77		1.74*	1.7*		1.36	1.35	
Others		1.23	1.23		1.44	1.4		1.03	1.03	
<b>Education level</b>										0.02(0.98)
None/Informal										
Primary		0.85	0.85		0.73	0.73		0.69	0.69	
Secondary and higher		0.82	0.82		0.76	0.76		0.74	0.73	
<b>Year of ART initiation</b>										0.7(0.49)
2015										
2016		1.54	1.54		0.81	0.81		1.13	1.15	
2017		1.43	1.4		0.99	0.99		1.02	1.04	
<b>WHO Stage</b>										0.21(0.81)
1										
2		0.79	0.79		0.79	0.80		1.04	1.04	
3		1.73	1.73		0.69	0.70		0.78	0.78	
4		0.60	0.60		0.82	0.80		0.87	0.90	
<b>Baseline immunosuppression</b>										0.14(0.87)
None (CD4≥500cells/ml)										
Mild (CD4≥350-499cells/ml)		1.18	1.1		0.82	0.82		0.91	0.91	
Advanced(CD4≥200-349cells/ml)		0.89	0.89		0.69	0.69		0.70	0.70	
Severe (CD4 < 200cells/ml)		0.64	0.64		0.55*	0.54 *		0.55*	0.55 **	
<b>Baseline TB status</b>										0.22 (0.80)
No signs or symptoms of TB										
Presumptive or confirmed TB		0.69	0.69		1.19	1.18		1.160	1.19	
On IPT		0.83	0.83		0.77	0.79		0.89	0.92	
<b>ART regimen at baseline</b>										0.58(0.56)
ABC or AZT/3TC/ ATVr or LPVr										
ABC or AZT/3TC/ EFV or NVP		2.19	2.19		1.46	1.47		3.19	3.20	
TDF/3TC/EFV or NVP		3.66	3.66		3.49	3.55		6.4*	6.47 *	
TDF/3TC/ATVr or LPVr		0.15	0.15		2.25	2.27		0.74	0.81	
Others		0.99	0.99		1.31	1.34		5.2	5.4	
<b>Continuity of care</b>										0.1 (0.90)
Retained										
LTF		0.35	0.35		0.19 **	0.19**		0.35 **	0.35**	
Interrupted care		0.40**	0.42**		0.41 **	0.41**		0.42 **	0.42**	

<b>LEVEL 2: Health facility</b>										
<b>Level of care</b>										0.39 (0.68)
Secondary										
Tertiary			0.90			0.90			0.80	
<b>Patient volume (AYLHIV)</b>										0.12 (0.89)
<200										
200-400			1.24			1.02			1.14	
>500			0.77			0.89			0.93	
<b>Designated AYFS facility</b>										0.91(0.40)
No										
Yes			1.33			0.92			1.06	
<b>Viral load testing coverage</b>										1.57(0.21)
			0.99			1.00			1.10	

<b>Random effects model</b>										
Health facility level										
Variance estimate (Facility level)	0.39*	0.38*	0.32	0.49**	0.44 **	0.44 **	0.34**	0.29 **	0.28 **	
Explained variation (%)	Ref	2.56 <sup>a</sup>	15.79 <sup>b</sup>	Ref	10.2 <sup>c</sup>	0 <sup>d</sup>	Ref	14.71 <sup>e</sup>	3.45 <sup>f</sup>	
Intra-facility ICC	0.11	0.10	0.09	0.13	0.12	0.12	0.09	0.08	0.08	

421 \*p<0.05, \*\*p<0.00; Model 1 is the null model; baseline model without any variable; Model 2 is model adjusted for  
 422 individual-level variables, Model 3 is additionally adjusted for facility-level covariates  
 423 a: Explained facility-level variance due to individual factors alone = (.39-.38)/.39 = 2.56%  
 424 b: Explained facility-level variance due to facility characteristics= (.38-.32)/.38 = 15.79 %  
 425 c: Explained facility-level variance due to individual factors = (.49-.44)/.49 = 10.2%  
 426 d: Explained facility-level variance due to facility characteristics= (.44-.44)/.44 = 0%  
 427 e: Explained facility-level variance due to individual factors alone = (.34-.29)/.34 = 14.71%  
 428 f: Explained facility-level variance due to facility characteristics= (.29-.28)/.29 = 3.45%

## 429        4. Discussion

430        In this multi-level and multiple group study, we estimated the relative contributions of individual-  
431        level and facility-level determinants to retention in care and viral suppression across ALHIV age-  
432        groups. We showed similarities and differences in magnitude and direction of effects across age-  
433        groups for individual level (age group, sex, ART regimen, and pattern of care continuity) and  
434        facility-level factors (viral load testing coverage) associated with retention in care and viral  
435        suppression. We discuss these findings according to the levels of influence.

436  
437        **Individual-level factors**  
438        Although we found differences in the magnitude and direction of effects for the individual-level  
439        variables, two factors emerged as consistent predictors across age-groups: Baseline ART regimen  
440        and pattern of retention.

441        Similar to other study findings (8,11,12,18), higher proportions (64.7%) of young adolescents were  
442        retained in care compared to older adolescents (56.4%) and young adults living with HIV (58.7%).  
443        Despite their higher rates of retention, young adolescents had comparatively much lower viral  
444        suppression rates (63.5%) compared to older adolescents (81.2%) and young adults (88.3%). Also,  
445        while the odds for viral suppression reduced with lower levels of retention with increasing age,  
446        there was no significant difference in odds for viral suppression among young adolescents retained  
447        in care and those who were lost to follow-up. Although these findings seem counterintuitive since  
448        better retention in care is expected to lead to higher rates of viral suppression, it corroborates  
449        findings from other studies (30–35) showing high rates of viral non-suppression among young  
450        adolescents despite perfect adherence, most notably among young adolescents initiated on  
451        AZT + 3TC + NVP/EFV. Young adolescents in our study were initiated predominantly on ART  
452        regimen AZT + 3TC + NVP/EFV( 63.2%), in contrast to older adolescents and young adults who  
453        were initiated predominantly on TDF/3TC/EFV or NVP (83.9 and 90.1% respectively). Moreover,  
454        the likelihood of achieving viral suppression irrespective of age-groups was highest with initiation  
455        on TDF/3TC/EFV or NVP regimen, reaching significance only among young adults ALHIV. These  
456        findings suggest a rise in regimen-specific disparity in viral outcomes, with increasing rates of viral  
457        non-suppression despite levels of adherence that should normally guarantee viral suppression. Such  
458        increases if not addressed could undermine other HIV prevention interventions.

459 Another reason we considered for the differential viral suppression between our age groups may  
460 be that substantial age-group differences exist by mode of HIV infection. Although we did not have  
461 enough information to characterize our cohort by mode of HIV infection, we speculate that the  
462 majority of younger adolescents in our study are adolescents perinatally infected with HIV  
463 compared to older adolescents and younger adults who we assume to be mostly behaviorally  
464 infected. Studies have shown that perinatally infected ALHIV are unique in their life-long  
465 experience with HIV infection, with many of them born in the era of mono- and dual-antiretroviral  
466 therapy, thus facing an increased likelihood of drug resistance (5,8,11,12)

467 We observed ART regimen specific effect differences on retention in care. Compared to ALHIV  
468 initiated on regimen ABC or AZT/3TC/ ATVr or LPVr, ALHIV initiated on other regimens than  
469 the previous ones, were less likely to be LTF or have interrupted care (i.e. not retained) in the three  
470 age groups. We speculate these differences to be due to drug side effects from ART which studies  
471 have shown to be a major barrier to adherence. Studies have suggested that, compared to patients  
472 who initiate ART after experiencing prior sicknesses, patients feeling healthy before commencing  
473 ART can have less motivation to tolerate the side effects associated with ART at different stages  
474 of care. The scenario is more likely to trigger disengagement with care among ALHIV who in the  
475 era of test and treat are generally more likely to initiate ART feeling healthy. The current HIV  
476 policy climate of “test and start” where laboratory and clinical assessments are no longer eligibility  
477 requirements for ART initiation may lead to an under-emphasis on clinical assessment processes  
478 including the management of side effects in favor of quicker ART initiations (36). While our study  
479 shows the benefit of early ART initiation to viral outcomes among ALHIV (i.e. likelihood of  
480 achieving viral suppression reduced with increasing immune-suppression at baseline, reaching  
481 statistical significance among older adolescent and young adults with severe baseline immune  
482 suppression) this finding points to an increased need to support ALHIV in balancing immediate  
483 needs and desires to live their normal lives with meeting the biomedical requirements for achieving  
484 viral suppression (clinic visits and treatment adherence).

485 We observed a preponderance of female ALHIV among our cohort with age, suggesting that female  
486 adolescents and young adult women represent a behaviorally vulnerable population. This supports  
487 previous findings from sub-Saharan Africa countries, where being young, female, and less-  
488 educated increases the chances for transgenerational HIV transmission (36). Combined with high

489 adolescent fertility rates in Nigeria, poor retention, and low viral suppression rates among older  
490 adolescents and young adults in our study might undermine ongoing efforts at eliminating HIV  
491 mother-to-child transmission. However, we also found other gender-specific disparities within our  
492 cohort in which male young adult ALHIVs had a higher likelihood of interrupting care or being  
493 LTF, and male older adolescent ALHIV being less likely to achieve viral suppression.

494 Our findings on sex differences suggest the need to factor in gender considerations as services  
495 become increasingly differentiated for ALHIV. Studies have shown promising practices among the  
496 different approaches targeting men/male for improved HIV testing, prevention, treatment, care and  
497 support services(37–47)

498

### 499 **Health facility level factors**

500 We found significant variation in outcomes attributable to differences at the health facility level.  
501 The variations across facilities remained statistically significant, even after controlling for  
502 individual- and facility-level factors (Models 2 and 3).

503 Although compared to individual-level factors facility-level characteristics accounted for a higher  
504 proportion of the total variance observed, the magnitude of this facility-level contribution to  
505 variance (i.e. facility effects) differed between ALHIV age-groups. For retention in care, higher  
506 increases due to facility effects were observed among young adolescents and young adults than  
507 among older adolescents. For viral suppression, there was no change in variance from facility  
508 effect, only a modest increase among young adults and a much higher increase in young  
509 adolescents. These differences suggest that interventions at the level of health services may be less  
510 effective than those targeting individual-level determinants for improving viral outcomes among  
511 older adolescents. This supports other studies showing that adolescent-focused health services  
512 interventions, though desirable, are not uniformly effective across all adolescent age-groups (48).

513 We found that an increase in viral-load testing at facility-level reduced the likelihood of non-  
514 retention among ALHIV. This might be explained by the high benefit perception of PLHIV  
515 concerning laboratory indicator measures (e.g. CD4, viral load test) for health status assessment.  
516 Some studies have shown that inability to access such tests often triggers disengagement with care  
517 (49–51). As the role of CD4 counts become increasingly outdated with the implementation of test

518 and treat policies, increased coverage of routine viral load testing is necessary to encourage and  
519 sustain this positive health-seeking behavior. Furthermore, given disproportionately high rates of  
520 virological failure and sub-optimal retention among ALHIV, scale-up for viral load testing would  
521 allow providers to make informed decisions on counseling, support, and the management of  
522 treatment regimens(52).

523

## 524 **Clinical implications**

525 Taken together, our study shows the need for both individual and health services interventions for  
526 ALHIV to be both broad-based and targeted. We showed that some factors at the individual and  
527 facility level (ART regimen, the pattern of retention in care, baseline immune suppression, viral  
528 load testing coverage) appear to be important predictors of outcomes in all ALHIV age-groups.  
529 These common factors appear to represent the base of a hierarchy of factors driving outcomes  
530 across all ALHIV and might be important entry points for modifying health services to better  
531 respond to ALHIV needs as part of a minimum package of services. This would include improving  
532 responsiveness to gender and age-specific needs, improving capacity for active case-finding and  
533 monitoring for retention in care, increased capacity for viral load testing, capacity building for all  
534 care providers to provide clinical care including pharmacovigilance, and monitoring of ART side  
535 effects.

536

## 537 **Study limitations**

538 Our findings should be interpreted in light of some important limitations. Although we imputed for  
539 missing information to minimize bias, the possibility of non-differential errors cannot be ruled out.  
540 Due to differences in the age-group cohort sizes, there was greater power to detect covariate effect  
541 sizes among older adolescents and young adults age-groups, compared to young adolescents.  
542 Although case-finding was conducted for those ALHIV who were not retained in care, the  
543 percentage of these patients who returned to clinical care and had viral load assessment was low  
544 and may not be representative of their respective categories. We also lacked information to  
545 categorize our adolescent cohort by modes of transmission (perinatal vs behavioral infected) and  
546 previous exposure to antiretrovirals. Despite our use of multiple imputations to address missing

547 data, we still cannot completely rule out some bias in our estimates given that health facilities with  
548 more missing data may also be the ones with poorer outcomes on the aggregate. Lastly, our study  
549 was carried out within the context of healthcare facilities receiving PEPFAR support. Findings may  
550 therefore not be generalizable to other ALHIV receiving care at health facilities not supported by  
551 PEPFAR who may differ in patient outcomes. Despite attempting to delineate the different levels  
552 of effects in our multilevel modeling our study still did not fully account for variations in outcomes  
553 at facility levels. This unobserved heterogeneity suggests the existence of other important  
554 explanatory factors that were not measured in our study.

## 555 **Conclusions**

556 Our study supports our hypothesis that important differences exist in health service conditions  
557 between healthcare facilities that can explain variations in treatment outcomes among ALHIV. We  
558 also demonstrate key individual(ART regimen, baseline immune suppression, sex) and facility-  
559 level factors (facility-level viral-load testing) that may serve as entry points for both broad-based  
560 and targeted interventions to improve outcomes among ALHIV. Despite limited data to explore  
561 the whole range of factors at individual and service delivery levels potentially affecting treatment  
562 continuity and viral load suppression, we demonstrate a need to better understand and unpack these  
563 potentially modifiable factors at the individual- and facility-level to design interventions that ensure  
564 equity of among all ALHIV groups and ensure that no one is left behind.

565

## 566 **Competing interests**

567 The authors declare no competing interest

568

## 569 **Authors' contributions**

570 OAB conceived the study, conducted the analysis, and wrote all drafts of the manuscript. All  
571 authors provided critical reviews of the draft. All authors read and approved of the final draft

572

## 573 **Acknowledgments**

574 The authors acknowledge enabling support from APIN management during the conduct of this  
575 study. We also thank program managers and health workers who provide services to people living

576 with HIV. Finally, we thank all adolescents and youths living with HIV whose consent to having  
577 their information used for research purposes has made this study possible

## 578 **Funding**

579 The data on which this study is based is from a project funded by the US Presidents Emergency  
580 Plan for AIDS (PEPFAR), awarded through the Center for Disease Control. The funder had no role  
581 in the conduct and writing of this study. OAB received doctoral research funding from the Belgium  
582 Directorate-General for Development Cooperation (DGD) awarded through the Institute of  
583 Tropical Medicine Antwerp, Belgium

584

## 585 **References**

586

- 587 1. Tsondai PR, Sohn AH, Phiri S, Sikombe K, Sawry S, Chimbetete C, et al. Characterizing the  
588 double-sided cascade of care for adolescents living with HIV transitioning to adulthood across  
589 Southern Africa. *J Int AIDS Soc.* 2020;23(1):e25447.
- 590 2. WHO. UNAIDS Update: active involvement of young people is key to ending the AIDS  
591 epidemic by 2030. WHO Geneva; 2017.
- 592 3. Zanoni BC, Mayer KH. The adolescent and young adult HIV cascade of care in the United  
593 States: exaggerated health disparities. *AIDS Patient Care STDs.* 2014 Mar;28(3):128–35.
- 594 4. Said M, Bartlett AW. Immune Dysfunction and Antiretroviral Therapy Challenges in  
595 Children and Adolescents Living with Human Immunodeficiency Virus. *Innate Immun*  
596 *Health Dis* [Internet]. 2020 Apr 27 [cited 2020 May 29]; Available from:  
597 [https://www.intechopen.com/online-first/immune-dysfunction-and-antiretroviral-therapy-](https://www.intechopen.com/online-first/immune-dysfunction-and-antiretroviral-therapy-challenges-in-children-and-adolescents-living-with-hum)  
598 [challenges-in-children-and-adolescents-living-with-hum](https://www.intechopen.com/online-first/immune-dysfunction-and-antiretroviral-therapy-challenges-in-children-and-adolescents-living-with-hum)
- 599 5. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, et al.  
600 Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents  
601 compared with adults in southern Africa. *J Acquir Immune Defic Syndr* 1999. 2009 May  
602 1;51(1):65–71.
- 603 6. Ending the AIDS epidemic for adolescents, with adolescents. :32.
- 604 7. Wang H, Wolock TM, Carter A, Nguyen G, Kyu HH, Gakidou E, et al. Estimates of global,  
605 regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global  
606 Burden of Disease Study 2015. *Lancet HIV.* 2016 Aug 1;3(8):e361–87.
- 607 8. Slogrove AL, Sohn AH. The global epidemiology of adolescents living with HIV: Time for  
608 more granular data to improve adolescent health outcomes. *Curr Opin HIV AIDS.* 2018  
609 May;13(3):170–8.

- 610 9. Fast-track commitments to end AIDS by 2030 [Internet]. [cited 2020 May 29]. Available  
611 from: <https://www.unaids.org/en/resources/documents/2016/fast-track-commitments>
- 612 10. Young people, HIV and AIDS [Internet]. Avert. 2015 [cited 2020 Jun 21]. Available from:  
613 [https://www.avert.org/professionals/hiv-social-issues/key-affected-populations/young-](https://www.avert.org/professionals/hiv-social-issues/key-affected-populations/young-people)  
614 [people](https://www.avert.org/professionals/hiv-social-issues/key-affected-populations/young-people)
- 615 11. Collaboration TCI for PHE and R (CIPHER) GC, Slogrove AL, Schomaker M, Davies M-A,  
616 Williams P, Balkan S, et al. The epidemiology of adolescents living with perinatally acquired  
617 HIV: A cross-region global cohort analysis. *PLOS Med*. 2018 Mar 1;15(3):e1002514.
- 618 12. Slogrove AL, Mahy M, Armstrong A, Davies M-A. Living and dying to be counted: What we  
619 know about the epidemiology of the global adolescent HIV epidemic. *J Int AIDS Soc*.  
620 2017;20(S3):21520.
- 621 13. Reif LK, Abrams EJ, Arpadi S, Elul B, McNairy ML, Fitzgerald DW, et al. Interventions to  
622 Improve Antiretroviral Therapy Adherence Among Adolescents and Youth in Low- and  
623 Middle-Income Countries: A Systematic Review 2015–2019. *AIDS Behav* [Internet]. 2020  
624 Mar 9 [cited 2020 May 29]; Available from: <https://doi.org/10.1007/s10461-020-02822-4>
- 625 14. Kranzer K, Simms V, Bandason T, Dauya E, McHugh G, Munyati S, et al. Economic  
626 incentives for HIV testing by adolescents in Zimbabwe: a randomised controlled trial. *Lancet*  
627 *HIV*. 2018 Feb;5(2):e79–86.
- 628 15. Reif LK, Bertrand R, Benedict C, Lamb MR, Rouzier V, Verdier R, et al. Impact of a youth-  
629 friendly HIV clinic: 10 years of adolescent outcomes in Port-au-Prince, Haiti. *J Int AIDS Soc*.  
630 2016;19(1):20859.
- 631 16. Ruria EC, Masaba R, Kose J, Woelk G, Mwangi E, Matu L, et al. Optimizing linkage to care  
632 and initiation and retention on treatment of adolescents with newly diagnosed HIV infection:  
633 *AIDS*. 2017 Jul;31:S253–60.
- 634 17. Teasdale CA, Alwar T, Chege D, Fayorsey R, Hawken MP, Abrams EJ. Impact of Youth and  
635 Adolescent Friendly Services on Retention of 10–24-Year-Olds in HIV Care and Treatment  
636 Programs in Nyanza, Kenya. *J Acquir Immune Defic Syndr* 1999. 2016 Feb 1;71(2):e56–9.
- 637 18. Lamb MR, Fayorsey R, Nuwagaba-Biribonwoha H, Viola V, Mutabazi V, Alwar T, et al.  
638 High attrition before and after ART initiation among youth (15-24 years of age) enrolled in  
639 HIV care. *AIDS Lond Engl*. 2014 Feb 20;28(4):559–68.
- 640 19. Rongkavilit C, Naar-King S, Wang B, Panthong A, Bunupuradah T, Parsons JT, et al.  
641 Motivational interviewing targeting risk behaviors for youth living with HIV in Thailand.  
642 *AIDS Behav*. 2013 Jul;17(6):2063–74.
- 643 20. Kaihin R, Kasatpibal N, Chitreechuer J, Grimes RM. Effect of an Empowerment Intervention  
644 on Antiretroviral Drug Adherence in Thai Youth. *Behav Med Wash DC*. 2015;41(4):186–94.



- 645 21. Bhana A, Mellins CA, Petersen I, Alicea S, Myeza N, Holst H, et al. The VUKA Family  
646 Program: Piloting a family-based psychosocial intervention to promote health and mental  
647 health among HIV infected early adolescents in South Africa. *AIDS Care* [Internet]. 2014 Jan  
648 [cited 2020 Feb 8];26(1). Available from:  
649 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3838445/>
- 650 22. Black RE, Allen LH, Bhutta ZA, Caulfield LE, de Onis M, Ezzati M, et al. Maternal and child  
651 undernutrition: global and regional exposures and health consequences. *The Lancet*. 2008 Jan  
652 19;371(9608):243–60.
- 653 23. Smith P, Wallace M, Bekker L-G. Adolescents' experience of a rapid HIV self-testing device  
654 in youth-friendly clinic settings in Cape Town South Africa: a cross-sectional community  
655 based usability study. *J Int AIDS Soc*. 2016;19(1):21111.
- 656 24. Mavhu W, Willis N, Mufuka J, Bernays S, Tshuma M, Mangenah C, et al. Effect of a  
657 differentiated service delivery model on virological failure in adolescents with HIV in  
658 Zimbabwe (Zvandiri): a cluster-randomised controlled trial. *Lancet Glob Health*. 2020 Feb  
659 1;8(2):e264–75.
- 660 25. Badejo OA, Menson WNA, Sam-Agudu NA, Pharr J, Ereka S, Bruno T, et al. Pediatric to  
661 adult healthcare transitioning for adolescents living with HIV in Nigeria: A national survey.  
662 *PLOS ONE*. 2018 Jun 12;13(6):e0198802.
- 663 26. Oladele EA, Badejo OA, Obanubi C, Okechukwu EF, James E, Ow'honda G, et al. Bridging  
664 the HIV treatment gap in Nigeria: examining community antiretroviral treatment models. *J  
665 Int AIDS Soc*. 2018;21(4):e25108.
- 666 27. Global AIDS Monitoring 2020 -- Indicators for monitoring the 2016 Political Declaration on  
667 Ending AIDS. :176.
- 668 28. Joint United Nations Programme on HIV/AIDS (UNAIDS). 90-90-90: an ambitious treatment  
669 target to help end the AIDS epidemic [Internet]. UNAIDS; 2014. Available from:  
670 [https://www.unaids.org/sites/default/files/media\\_asset/90-90-90\\_en\\_0.pdf](https://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf)
- 671 29. von Hippel P. HOW\_MANY\_IMPUTATIONS: Stata module to determine required number  
672 of imputations [Internet]. 2018. Available from:  
673 <https://EconPapers.repec.org/RePEc:boc:bocode:s458452>
- 674 30. Natukunda J, Kirabira P, Ong KIC, Shibanuma A, Jimba M. Virologic failure in HIV-positive  
675 adolescents with perfect adherence in Uganda: a cross-sectional study. *Trop Med Health*. 2019  
676 Jan 17;47(1):8.
- 677 31. Sovershaeva E, Shamu T, Wilsgaard T, Bandason T, Flægstad T, Katzenstein D, et al. Patterns  
678 of detectable viraemia among children and adults with HIV infection taking antiretroviral  
679 therapy in Zimbabwe. *Int J Infect Dis*. 2019 Jan 1;78:65–71.

- 680 32. McHugh G, Simms V, Dauya E, Bandason T, Chonzi P, Metaxa D, et al. Clinical outcomes  
681 in children and adolescents initiating antiretroviral therapy in decentralized healthcare settings  
682 in Zimbabwe. *J Int AIDS Soc.* 2017 Jan 1;20(1):21843.
- 683 33. Mossoro-Kpinde CD, Gody J-C, Mboumba Bouassa R-S, Mbitikon O, Jenabian M-A, Robin  
684 L, et al. High levels of virological failure with major genotypic resistance mutations in HIV-  
685 1-infected children after 5 years of care according to WHO-recommended 1st-line and 2nd-  
686 line antiretroviral regimens in the Central African Republic: A cross-sectional study.  
687 *Medicine (Baltimore).* 2017 Mar;96(10):e6282.
- 688 34. Chimukangara B, Manasa J, Mitchell R, Nyabadza G, Katzenstein D, Masimirembwa C.  
689 Community Based Antiretroviral Treatment in Rural Zimbabwe. *AIDS Res Hum*  
690 *Retroviruses.* 2017 Sep 13;33(12):1185–91.
- 691 35. Muri L, Gamell A, Ntamatungiro A, Glass T, Luwanda L, Battegay M, et al. Development of  
692 HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an  
693 emerging public health concern. *Aids.* 2017 Jan 2;31(1):61–70.
- 694 36. Adeola J, Badejo OA, Ahonkhai A, Okonkwo P, Aboh Akande P, Evans CT, et al. Effect of  
695 Baseline Symptom Manifestations on Retention in Care and Treatment among HIV-Infected  
696 Patients in Nigeria. *J Int Assoc Provid AIDS Care JIAPAC.* 2020 Jan  
697 1;19:2325958220903575.
- 698 37. Stender SC, Rozario A. “Khotla Bophelong Bo Botle”: a gathering of men for health. *J Int*  
699 *AIDS Soc.* 2020 Jun 1;23(S2):e25511.
- 700 38. Shapiro AE, van Heerden A, Krows M, Sausi K, Sithole N, Schaafsma TT, et al. An  
701 implementation study of oral and blood-based HIV self-testing and linkage to care among  
702 men in rural and peri-urban KwaZulu-Natal, South Africa. *J Int AIDS Soc.* 2020 Jun  
703 1;23(S2):e25514.
- 704 39. Gottert A, Pulerwitz J, Heck CJ, Cawood C, Mathur S. Creating HIV risk profiles for men in  
705 South Africa: a latent class approach using cross-sectional survey data. *J Int AIDS Soc.* 2020  
706 Jun 1;23(S2):e25518.
- 707 40. Dovel K, Dworkin SL, Cornell M, Coates TJ, Yeatman S. Gendered health institutions:  
708 examining the organization of health services and men’s use of HIV testing in Malawi. *J Int*  
709 *AIDS Soc.* 2020 Jun 1;23(S2):e25517.
- 710 41. Bhattacharjee P, Isac S, Musyoki H, Emmanuel F, Olango K, Kuria S, et al. HIV prevalence,  
711 testing and treatment among men who have sex with men through engagement in virtual  
712 sexual networks in Kenya: a cross-sectional bio-behavioural study. *J Int AIDS Soc.* 2020 Jun  
713 1;23(S2):e25516.
- 714 42. Mwango LK, Stafford KA, Blanco NC, Lavoie M-C, Mujansi M, Nyirongo N, et al. Index  
715 and targeted community-based testing to optimize HIV case finding and ART linkage among  
716 men in Zambia. *J Int AIDS Soc.* 2020 Jun 1;23(S2):e25520.

- 717 43. Barnabas RV, van Heerden A, McConnell M, Szpiro AA, Krows ML, Schaafsma TT, et al.  
718 Lottery incentives have short-term impact on ART initiation among men: results from a  
719 randomized pilot study. *J Int AIDS Soc.* 2020 Jun 1;23(S2):e25519.
- 720 44. Napierala S, Bair EF, Marcus N, Ochwal P, Maman S, Agot K, et al. Male partner testing and  
721 sexual behaviour following provision of multiple HIV self-tests to Kenyan women at higher  
722 risk of HIV infection in a cluster randomized trial. *J Int AIDS Soc.* 2020 Jun 1;23(S2):e25515.
- 723 45. Osler M, Cornell M, Ford N, Hilderbrand K, Goemaere E, Boulle A. Population-wide  
724 differentials in HIV service access and outcomes in the Western Cape for men as compared  
725 to women, South Africa: 2008 to 2018: a cohort analysis. *J Int AIDS Soc.* 2020 Jun  
726 1;23(S2):e25530.
- 727 46. Makusha T, van Rooyen H, Cornell M. Reframing the approach to heterosexual men in the  
728 HIV epidemic in sub-Saharan Africa. *J Int AIDS Soc.* 2020 Jun 1;23(S2):e25510.
- 729 47. Grimsrud A, Ameyan W, Ayieko J, Shewchuk T. Shifting the narrative: from “the missing  
730 men” to “we are missing the men.” *J Int AIDS Soc.* 2020 Jun 1;23(S2):e25526.
- 731 48. Sam-Agudu NA, Folayan MO, Haire BG. Program implementation gaps and ethical issues in  
732 the prevention of HIV infection among infants, children, and adolescents in sub-Saharan  
733 Africa. *Pediatr Res.* 2020 Jan 1;87(2):406–13.
- 734 49. Rachlis B, Bakoyannis G, Easterbrook P, Genberg B, Braithwaite RS, Cohen CR, et al.  
735 Facility-Level Factors Influencing Retention of Patients in HIV Care in East Africa. *PLOS*  
736 *ONE.* 2016 Aug 10;11(8):e0159994.
- 737 50. Renju J, Moshabela M, McLean E, Ddaaki W, Skovdal M, Odongo F, et al. ‘Side effects’ are  
738 ‘central effects’ that challenge retention in HIV treatment programmes in six sub-Saharan  
739 African countries: a multicountry qualitative study. *Sex Transm Infect* [Internet]. 2017 Jul 1  
740 [cited 2020 May 30];93(Suppl 3). Available from:  
741 [https://sti.bmj.com/content/93/Suppl\\_3/e052971](https://sti.bmj.com/content/93/Suppl_3/e052971)
- 742 51. Cluver L, Pantelic M, Toska E, Orkin M, Casale M, Bungane N, et al. STACKing the odds  
743 for adolescent survival: health service factors associated with full retention in care and  
744 adherence amongst adolescents living with HIV in South Africa. *J Int AIDS Soc.* 2018  
745 Sep;21(9):e25176–e25176.
- 746 52. Marcus R, Ferrand RA, Kranzer K, Bekker L-G. The case for viral load testing in adolescents  
747 in resource-limited settings. *J Int AIDS Soc.* 2017 Nov;20:e25002.

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762